ArticleWorld journal of clinical pediatrics2026
Bovine colostrum for prevention of recurrent urinary tract infections in susceptible children: A randomized controlled trial.
Article in World journal of clinical pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent urinary tract infections (UTIs) in children with congenital anomalies of the kidney and urinary tract (CAKUT) are a major cause of deterioration of kidney functions and possibly, renal scarring. Rising antimicrobial resistance necessitates alternative preventive strategies. Bovine colostrum (BC), a bioactive prebiotic, has emerged as a promising adjuvant therapy in upper respiratory and gastrointestinal (GIT) infections. Given the shared mucosal immune mechanisms, the urinary tract may represent a suitable target for this preventive strategy to reduce UTI recurrence.
aimTo evaluate the potential role of oral BC as an adjuvant therapy for preventing recurrent UTIs in children with CAKUT.
methodsThis randomized, double-blinded, placebo-controlled trial enrolled 60 children (< 18 years) with CAKUT and culture-confirmed recurrent UTIs. Children with urinary stones or endo-urinary devices were excluded. Participants were randomized to receive either oral BC sachets (
resultsThe two study groups were comparable in age, sex, and chronic kidney disease stage (
conclusionBC supplementation may reduce cystitis, as well as respiratory and GIT infections, in children with CAKUT. The observed month-specific reduction in UTIs suggests a possible cumulative benefit with continued supplementation, warranting further research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.